Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xagrid vs Hydroxyurea in high-risk essential thrombocythaemia
NCT00202644Phase 4Completed
- Sponsor
- Takeda
- Start
- Jan 2006
- Primary completion
- Dec 2015
- Countries
- 6
01
Overview
A Phase 4 trial of anagrelide in essential thrombocythemia (ET), sponsored by Takeda. Started Jan 2006; status: completed.
02
Drugs
anagrelide
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT00202644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202644.